Perioperative management of chronic anticoagulation
What it is
Perioperative management of chronic anticoagulation requires an assessment of two things at once: the patients risk for thromboembolism, and the risk of bleeding from the surgical procedure. The first decides whether the patient needs bridging, the second decides how the anticoagulant is stopped.
Causes and risk
High-risk patients are of four kinds: first, those with mechanical heart valves; second, a stroke or TIA within the past 3 months; third, venous thromboembolism within the past 3 months; fourth, coronary stenting within the previous 12 months. In atrial fibrillation the decision rests on the CHA2DS2-VASc score, and two numbers are given for it: first, 6 or above, at which the patient should receive bridging therapy; second, 3, which is low risk for thromboembolism. The score itself is made of eight items: first CHF; second HTN; then Age ≥75, which is worth 2 points; DM; Stroke/TIA, which is worth 2 points; Vascular disease; Age 65-74; and Sex female. The level at which to anticoagulate is ≥2 in men and ≥3 in women, which is a different question from bridging.
How it is treated
High-risk patients require bridging therapy with low molecular weight heparin, while patients at low risk do not require bridging anticoagulation. For low-risk patients it is recommended that warfarin be discontinued 5 days before surgery and restarted 12 to 24 hours after the operation. When the surgery itself carries a high risk for bleeding, it is preferable to stop the warfarin 5 days before the operation. What is used to adjust the dose differs by drug: the INR is used to adjust warfarin dosing and the partial thromboplastin time is used to adjust heparin dosing, while the novel anticoagulants require dosage adjustments based on renal function, with no dosing recommendations based on liver function or albumin level.